drug · antibody

HYMPAVZI

updated 2mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication.

targets

Tissue factor pathway inhibitor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

HYMPAVZI

trade names

Hympavzi

generic

MARSTACIMAB-HNCQ

MOA

12.1 Mechanism of Action Marstacimab‑hncq is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of TFPI to neutralize TFPI activity and enhance coagulation. TFPI is the primary inhibitor of the extrinsic coagulation cascade and negatively regulates thrombin generation within the extrinsic pathway of coagulation by inactivating the protease functions of FXa/FVIIa/TF complex. TFPI binds to and inhibits the factor Xa active site via its second Kunitz inhibitor domain (K2).

indication

1 INDICATIONS AND USAGE HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. ( 1 )

HYMPAVZI

targets

all catalysts(0)

News(0)

Report a data issue

🐶 often sniffed alongside

comments(0)